Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LY-364947
Cat. No.:
OB0225LY-0183
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
LY-364947 is a selective inhibitor that targets the fibroblast growth factor signaling pathway and contributes to studies of cell proliferation and migration.
Synonym:
LY 364947; HTS466284; 396129-53-6; 4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)quinoline; TGF-beta RI kinase inhibitor; 4-(5-Pyridin-2-yl-1H-pyrazol-4-yl)quinoline; 4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]quinoline; 3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole
CAS No.:
396129-53-6
Compound CID:
447966
Formula:
C17H12N4
Formula Weight:
272.3
Specification
Relative Density:
1.283 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
LY-364947 can be used in cell biology studies or play an important role in tumor microenvironment studies.
Library Information
Targets:
Kinases; TGF-beta/Smad
Receptors:
CK1δ; MLK-7K; RIPK2; TGF-β receptor; TGFβRI; TGFβRII
Pathways:
Apoptosis; NF-κB; MAPK; Metabolism; Stem cells
Plate Number:
AOCL-3
Plate Location:
c6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
2 mM DMSO
DMSO Max Solubility:
7.5 mg/mL; 27.54 mM
ALogP:
3.203
HBA_Count:
3
HBD_Count:
1
Rotatable Bond:
2
